Mitsubishi UFJ Trust & Banking Corp Has $9.95 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mitsubishi UFJ Trust & Banking Corp decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 94,162 shares of the medical equipment provider’s stock after selling 241 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Zimmer Biomet were worth $9,946,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Intech Investment Management LLC increased its position in Zimmer Biomet by 21.3% during the 3rd quarter. Intech Investment Management LLC now owns 2,379 shares of the medical equipment provider’s stock worth $257,000 after purchasing an additional 417 shares in the last quarter. FMR LLC grew its stake in shares of Zimmer Biomet by 27.6% during the third quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after buying an additional 162,384 shares during the last quarter. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at $35,000. Townsquare Capital LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at $341,000. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Zimmer Biomet by 163.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 44,554 shares of the medical equipment provider’s stock valued at $4,810,000 after acquiring an additional 27,673 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $124.15.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.95% of the stock is owned by insiders.

Zimmer Biomet Stock Up 0.1 %

Zimmer Biomet stock opened at $112.21 on Friday. The company has a market capitalization of $22.34 billion, a PE ratio of 25.22, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $131.61. The firm’s fifty day moving average is $107.18 and its 200 day moving average is $107.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm posted $2.20 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.